Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Prokaryotics, Inc. logo — Antibacterial discovery organization committed to bringing f...

Prokaryotics, Inc.

Antibacterial discovery organization committed to bringing forth innovative therapeutics to address AMR

Founded 2017 United States Union, United States 8 employees Total: $2.50M Biopharma, Biotechnology +1

General Information

Company Name Prokaryotics, Inc.
Founded Year 2017
Location United States Union, United States
Employees 8
Industries Biopharma, Biotechnology, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with Prokaryotics, Inc.. To contact Prokaryotics, Inc., visit prokaryotics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Prokaryotics, Inc. compare?

A PDF of Prokaryotics, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Prokaryotics, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Prokaryotics, Inc.

Prokaryotics, Inc., a biotechnology startup established in 2017, focuses on the discovery and development of innovative therapeutics to combat antimicrobial resistance. The company, headquartered in the United States, has emerged from the licensing of several novel antibiotic programs from Merck & Co., Inc. Its team, comprising former senior scientists from Merck, including the head of the Antimicrobial Early Discovery Unit, is dedicated to optimizing early-stage programs targeting both Gram-negative and Gram-positive bacteria. Prokaryotics has secured worldwide rights to develop, manufacture, and commercialize pre-clinical assets and programs, positioning itself as an authentic antibacterial discovery organization dedicated to addressing the challenge of multidrug-resistant bacteria and the escalating global crisis of antibiotic resistance. The company received a $2.50M grant investment on 08 March 2018 from the National Institutes of Health, reflecting confidence in its mission and approach. Operating at the intersection of the Biopharma, Biotechnology, and Pharmaceutical industries, Prokaryotics aims to pave the way for groundbreaking solutions in the fight against antimicrobial resistance.

Business keywords: antibacterial discovery, therapeutics, AMR, antibiotic resistance, biopharmaceutical, multidrug resistant bacteria, antibiotic classes, bacterial infections, outer membrane biogenesis, drug development, scientific excellence, global crisis, pre-clinical assets, Gram-negative and Gram-positive bacteria

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $2.50M 1
National Institute of Health
National Institute of Health
01 Mar 2018

Prokaryotics, Inc. Alternatives & Competitors

View All Alternatives
Prokaryotics, Inc. vs
SelectX Pharmaceuticals
SelectX Pharmaceuticals United States

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development...

Series B
6 employees
Biotechnology, Health Care
Prokaryotics, Inc. vs
Synereca Pharmaceuticals
Synereca Pharmaceuticals

Pioneering orally active drugs to rejuvenate antibiotic efficacy against lung, urinary tract, and sk...

Venture round
Biotechnology, Health Care
Prokaryotics, Inc. vs
Zikani Therapeutics
Zikani Therapeutics

A new era in antibiotic treatment targeting resilient gram-negative bacteria, delivering advanced or...

Series A
Biotechnology, Life Sciences
View all alternatives

FAQ About Prokaryotics, Inc.

Antibacterial discovery organization committed to bringing forth innovative therapeutics to address AMR
Prokaryotics, Inc. was founded in 2017.
Prokaryotics, Inc. is headquartered in Union, United States.
Prokaryotics, Inc. operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on antibacterial discovery, therapeutics, AMR and antibiotic resistance.
Prokaryotics, Inc. has approximately 8 employees.
Prokaryotics, Inc. has completed 1 funding round, raising a total of $2.50M.
Top alternatives and competitors to Prokaryotics, Inc. include SelectX Pharmaceuticals, Synereca Pharmaceuticals, Zikani Therapeutics, Sealife PHARMA® GMBH, Spero Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Prokaryotics, Inc. and SelectX Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Prokaryotics, Inc., https://bouncewatch.com/company/prokaryotics-inc, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout